SALT LAKE CITY / Feb 03, 2025 / Business Wire / Varex Imaging Corporation (Nasdaq: VREX) today announced that it has received orders for non-intrusive cargo inspection systems valued at approximately $14 million USD. The orders are for the recently launched high energy inspection systems, VXP-6 Portal and VXM-6 Mobile systems for cargo and vehicle inspection, which are designed to assist in securing ports and borders.
Varex Imaging CEO, Sunny Sanyal, stated, “We are excited to see the interest and adoption in the newly launched product line of full screening systems.” Sanyal added, “Our reputation in high energy linear accelerators enables us to engage with end-users and strengthen our portfolio of offerings to our customers to help secure infrastructures worldwide.”
For more information about Varex’s non-intrusive cargo inspection systems, please contact your Varex representative or visit our website at https://www.vareximaging.com/security-solutions/.
About Varex
Varex Imaging Corporation is a leading innovator, designer, and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors, and other image processing solutions that are key components of X-ray imaging systems, as well as X-ray imaging systems for industrial applications. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate the company’s X-ray sources, digital detectors, connecting devices, and imaging software in their systems to detect, diagnose, protect, and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,300 people located in North America, Europe, and Asia. For more information visit vareximaging.com.
Forward Looking Statements
This news release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning interest in and adoption and performance of our products and systems; strengthening our portfolio of offerings; and impact on safety and security of infrastructures; and any statements using the terms “expect,” “could,” “may,” “designed,” and “possible” or similar statements are forward-looking statements that involve risks and uncertainties that could cause our actual results and the outcome and timing of certain events to differ materially from those projected or management’s current expectations. Any forward-looking statement made by us in this news release speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Varex assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.
| Last Trade: | US$11.97 |
| Daily Change: | 0.08 0.67 |
| Daily Volume: | 167,251 |
| Market Cap: | US$496.990M |
September 09, 2025 July 14, 2025 | |

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load